Dr. Veenstra’s primary research interests are the clinical, economic, and policy implications of precision medicine. His major research projects include evaluation of the cost effectiveness of population-level genomic screening, and evidence thresholds and preferences for precision medicine.

Dr. Veenstra’s research has been funded through grants from the National Human Genome Research Institute, Centers for Disease Control, and the National Cancer Institute.
He also has worked extensively with organizations such as the Academy of Managed Care Pharmacy (AMCP) and the Institute for Clinical and Economic Review (ICER) to further the practical application of cost-effectiveness analysis in managed care decision making.